Join Our Webinar on Prostate Care
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. MRI-targeted ultrasound-guided biopsies are the recommended methods for detection.
At Canon, we developed tailored solutions based on high-quality ultrasound imaging in combination with robust image fusion technology to perform transrectal and transperineal prostate biopsies quickly and effortlessly.
On June 13 (7 pm CEST / 1 pm EDT), during the webinar “Elevating Prostate Care: State-of-the-Art Ultrasound and Biopsy Solutions,” made possible by the Canon Medical Academy, all the techniques of MR/US fusion-guided biopsy will be presented, as well as additional technologies for multi-parametric ultrasound imaging of the prostate, and an outlook on potential applications for ultrasound-guided focal treatment will be discussed.
At Canon, we developed tailored solutions based on high-quality ultrasound imaging in combination with robust image fusion technology to perform transrectal and transperineal prostate biopsies quickly and effortlessly.
On June 13 (7 pm CEST / 1 pm EDT), during the webinar “Elevating Prostate Care: State-of-the-Art Ultrasound and Biopsy Solutions,” made possible by the Canon Medical Academy, all the techniques of MR/US fusion-guided biopsy will be presented, as well as additional technologies for multi-parametric ultrasound imaging of the prostate, and an outlook on potential applications for ultrasound-guided focal treatment will be discussed.
Elevating Prostate Care: State-of-the-Art Ultrasound and Biopsy Solutions
Sign up for the webinar and join Prof. Thomas Fischer, Dr. Katrien Gieraerts, and Dr. Matthias Jahnen as they discuss state-of-the-art ultrasound and biopsy solutions.
Program
Certificate
All delegates will receive a certificate of attendance.
* Note: The full name entered by joining the live webinar will be used to generate your name on the attendance certificate.
Program
- Introduction | Prof. Thomas Fischer
- Transperineal Fusion-Guided Prostate Biopsy Under Local Anaesthesia | Dr. Katrien Gieraerts
- Summary of Current Guidelines and Insights for the Prospective Randomized FAST-Trial | Dr. Matthias Jahnen
- Advanced Imaging of the Prostate and the Focal Therapy: Outlook and Initial Experience | Prof. Thomas Fischer
- Live Q&A
- Learn the value of MRI-fusion-guided biopsies for prostate
- Get practical tips regarding transrectal and transperineal approaches
- Understand the advantages of using advanced ultrasound techniques to evaluate the prostate
- Participate in the live Q&A to find answers to your questions
Certificate
All delegates will receive a certificate of attendance.
* Note: The full name entered by joining the live webinar will be used to generate your name on the attendance certificate.
Speakers and Presentations
Moderator and Speaker: Prof. Thomas Fischer, MD, PhD Radiologist, Head of Interdisciplinary Ultrasound Center,
Radiology, Executive Senior Physician, Department of Radiology
Charité University Medicine
Berlin, Germany
Presentation: Advanced Imaging of the Prostate and the Focal Therapy: Outlook and Initial Experience
Prostate cancer is the most common malignancy in men, and its incidence is continuously increasing. As with other malignant tumors, early and adequate diagnosis improves the chances of cure.
Patients who underwent organ-sparing treatment should be risk-stratified based on localization, extent, and actual Gleason score of the cancer. Real-time magnetic resonance imaging/ultrasound MRI/US-fusion-guided biopsy detects more clinically significant prostate cancers than conventional transrectal ultrasound (TRUS) biopsy. The aim of this session is to discuss state-of-the-art multi-parametric ultrasound techniques (mpUS) for MRI/US-fusion-guided biopsy in daily practice in comparison with transperineal MRI/US template or fusion biopsy, which has high sensitivity (>90%) in detecting aggressive prostate cancer.
Both techniques are useful in planning organ-sparing approaches (active surveillance, focal therapy).
In addition, we use SMI, shear-wave elastography, and ultrasound contrast agents to characterize focal prostate lesions and to monitor irreversible electroporation (IRE).
Discover More About the Moderator and Speaker
Radiology, Executive Senior Physician, Department of Radiology
Charité University Medicine
Berlin, Germany
Presentation: Advanced Imaging of the Prostate and the Focal Therapy: Outlook and Initial Experience
Prostate cancer is the most common malignancy in men, and its incidence is continuously increasing. As with other malignant tumors, early and adequate diagnosis improves the chances of cure.
Patients who underwent organ-sparing treatment should be risk-stratified based on localization, extent, and actual Gleason score of the cancer. Real-time magnetic resonance imaging/ultrasound MRI/US-fusion-guided biopsy detects more clinically significant prostate cancers than conventional transrectal ultrasound (TRUS) biopsy. The aim of this session is to discuss state-of-the-art multi-parametric ultrasound techniques (mpUS) for MRI/US-fusion-guided biopsy in daily practice in comparison with transperineal MRI/US template or fusion biopsy, which has high sensitivity (>90%) in detecting aggressive prostate cancer.
Both techniques are useful in planning organ-sparing approaches (active surveillance, focal therapy).
In addition, we use SMI, shear-wave elastography, and ultrasound contrast agents to characterize focal prostate lesions and to monitor irreversible electroporation (IRE).
Speaker: Dr. Katrien Gieraerts, MD Radiologist
AZ Sint-Jan Brugge AV
Bruges, Belgium
Presentation: Transperineal Fusion-Guided Prostate Biopsy Under Local Anaesthesia
MRI/ultrasound fusion-guided prostate biopsies in the transperineal approach have become the recommended biopsy procedure according to the guidelines of the European Association of Urology (EAU).
We established in our department a streamlined and timesaving protocol for this approach under local anaesthesia on a Canon Aplio i800 ultrasound scanner.
We have performed more than 500 biopsies with very good tolerance by the patients and a high detection rate for clinically significant cancers.
Discover More About the Speaker
AZ Sint-Jan Brugge AV
Bruges, Belgium
Presentation: Transperineal Fusion-Guided Prostate Biopsy Under Local Anaesthesia
MRI/ultrasound fusion-guided prostate biopsies in the transperineal approach have become the recommended biopsy procedure according to the guidelines of the European Association of Urology (EAU).
We established in our department a streamlined and timesaving protocol for this approach under local anaesthesia on a Canon Aplio i800 ultrasound scanner.
We have performed more than 500 biopsies with very good tolerance by the patients and a high detection rate for clinically significant cancers.
Speaker:
Dr. Matthias Jahnen, MD
Urology, Senior Resident
University Hospital Rechts der Isar, Technical University Munich
Munich, Germany
Presentation: Summary of Current Guidelines and Insights for the Prospective Randomized FAST-Trial
Current international guidelines recommend further diagnostic evaluation with prostate biopsy in men with suspicious mpMRI.
Given that, 5-10% of clinically significant PCa (defined as ≥ ISUP 2 PCa) may be missed by MRI-targeted biopsy alone, an additional 10-12 cores of systematic biopsy are still recommended and routinely performed in all biopsy-naïve patients.
The combination of systematic and MRI-targeted biopsy typically results in more than 12 and up to 25 biopsy cores, potentially increasing the risk of complications, discomfort, and peri-prostatic fibrosis. Therefore, strategies to reduce the number of biopsy cores have been increasingly investigated and are warranted.
Interim data from the FAST trial show that frozen section-assisted targeted prostate biopsy is feasible in men with suspicious mpMRI and provides rapid and reliable pathology results, allowing many men to avoid systematic biopsy.
Discover More About the Speaker
University Hospital Rechts der Isar, Technical University Munich
Munich, Germany
Presentation: Summary of Current Guidelines and Insights for the Prospective Randomized FAST-Trial
Current international guidelines recommend further diagnostic evaluation with prostate biopsy in men with suspicious mpMRI.
Given that, 5-10% of clinically significant PCa (defined as ≥ ISUP 2 PCa) may be missed by MRI-targeted biopsy alone, an additional 10-12 cores of systematic biopsy are still recommended and routinely performed in all biopsy-naïve patients.
The combination of systematic and MRI-targeted biopsy typically results in more than 12 and up to 25 biopsy cores, potentially increasing the risk of complications, discomfort, and peri-prostatic fibrosis. Therefore, strategies to reduce the number of biopsy cores have been increasingly investigated and are warranted.
Interim data from the FAST trial show that frozen section-assisted targeted prostate biopsy is feasible in men with suspicious mpMRI and provides rapid and reliable pathology results, allowing many men to avoid systematic biopsy.
Other webinars that may interest you
Disclaimers
Due to medical device regulatory reasons, not all products/services displayed on this Canon Medical Systems webpage are available in all countries or markets. Future availability of the products/service cannot also be guaranteed. Don't hesitate to contact your local Canon Medical Systems representative for further details.
